Likewise, steady-state exposure levels can be derived from the developed model, both for healthy subjects and subjects with T2D
Its worth noting that some GLP-1 medications are FDA-approved for diabetes, while others are specifically for weight loss
There are several types of GLP medications that engage different types of glucagon receptors, giving them different effects in different people: Single receptor agonists (GLP-1 only): Ozempic, Wegovy, Saxenda Dual receptor agonists (GLP-1 + GIP): Mounjaro, Zepbound Triple receptor agonists (GLP-1 + GIP + glucagon): in development early studies show even greater metabolic effects These medications are changing how we are able to ameliorate obesity, food addiction, insulin resistance, and cardiometabolic risks
Factor Xa A protein in the blood that plays a key role in forming blood clots
Jia, L., Cheng, L
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes
